Literature DB >> 3252244

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

J E Sweeney1, C F Höhmann, T H Moran, J T Coyle.   

Abstract

The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine's ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer's disease patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252244     DOI: 10.1016/0091-3057(88)90325-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  19 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Authors:  Derek S Wilkinson; Thomas J Gould
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

Review 3.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse.

Authors:  Thomas Freret; Véronique Lelong-Boulouard; Pierre Lecouflet; Katia Hamidouche; François Dauphin; Michel Boulouard
Journal:  Psychopharmacology (Berl)       Date:  2017-06-19       Impact factor: 4.530

Review 5.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

6.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

Review 7.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

8.  Therapeutic effect of THA on hemicholinium-3-induced learning impairment is independent of serotonergic and noradrenergic systems.

Authors:  J J Hagan; J H Jansen; F E Nefkens; T de Boer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Galanthamine in Alzheimer's disease : a new alternative to tacrine?

Authors:  M Rainer
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 10.  Psychobiological evidence for the distinction between episodic and semantic memory.

Authors:  M D Horner
Journal:  Neuropsychol Rev       Date:  1990-12       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.